Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetrahydrocannabinol + cannabidiol (BOL Pharma)
- Development stage
- Phase 3
- Lead developer
- BOL Pharma
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
THC + CBD is a cannabinoid-based sublingual tablet in preclinical development by BOL Pharma, an Israeli medical cannabis company. The drug combines two active cannabinoid ingredients — tetrahydrocannabinol (THC) and cannabidiol (CBD) — in a specific formulation containing 2.5 mg of THC and 30 mg of CBD. The drug is designed for sublingual administration (under the tongue), utilizing pharma-grade cannabinoid APIs sourced from BOL Pharma's own GAP-certified organic growing facilities and cGMP-certified production plant. While the specific molecular mechanism and disease indication for this particular pipeline candidate have not been publicly disclosed, the combination aims to leverage the synergistic effects of cannabinoids on the endocannabinoid system, primarily through interaction with cannabinoid receptors CB1 and CB2.
- Other names
- THC + CBDTHC + CBD sublingual tablet
02
Targets
CNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)TRPM8 (Transient receptor potential cation channel subfamily M member 8)TRPV1 (Transient receptor potential cation channel subfamily V member 1)TRPV2 (Transient receptor potential cation channel subfamily V member 2)
Beyond the preview
Go deeper on tetrahydrocannabinol + cannabidiol (BOL Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetrahydrocannabinol + cannabidiol (BOL Pharma).